Month in Review
September delivered two contrasting messages about treatment intensification. In medically inoperable early-stage NSCLC, SWOG/NRG S1914 showed that adding atezolizumab around SBRT did not improve survival and increased toxicity. In unresectable EGFR-mutated stage III disease, ADVANCE reported a striking PFS advantage with a chemotherapy-free strategy combining aumolertinib and radiotherapy, although the very small randomized population, premature termination and non-contemporary control arm make the result hypothesis-generating rather than practice-changing. Smaller studies explored AI-derived volumetric brain-metastasis response as a prognostic marker in CROWN and neoadjuvant immunochemotherapy followed by surgery in limited-stage SCLC.
The September peer-reviewed ADAURA and TAISHAN-302 updates were already covered in the OncoBrief WCLC 2026 special and are not repeated here.
Core Studies
Early-Stage NSCLC
Induction and consolidation atezolizumab with SBRT versus radiation alone in high-risk, early-stage NSCLC (SWOG/NRG S1914)
The Lancet
Study: Multicenter randomized phase III trial of SBRT with or without neoadjuvant, concurrent and adjuvant atezolizumab in high-risk T1–T3N0M0 NSCLC among patients who were medically inoperable or declined surgery. Of 417 randomized patients, 402 were eligible for the modified intention-to-treat analysis.
Key data: The trial closed for futility at its first interim analysis. At the updated analysis, the OS HR was 1.04 (95% CI 0.69–1.58), with estimated 2-year OS of 82% in both groups. Grade ≥3 adverse events occurred in 12% versus 3%, and two grade 5 respiratory events occurred with atezolizumab plus SBRT.
Why it matters: This is the first fully reported cooperative-group phase III trial testing checkpoint inhibition with SBRT in medically inoperable early-stage NSCLC, and it does not support routine addition of atezolizumab to SBRT. The result is particularly relevant after encouraging earlier phase II data had suggested a possible benefit.
Clinical context & caveats: The result applies to this atezolizumab/SBRT strategy and should not be generalized automatically to every immunotherapy-radiotherapy schedule or to surgically managed early-stage disease.
Unresectable Stage III / EGFR-Mutated NSCLC
Induction and concurrent aumolertinib with radiotherapy for EGFRm stage III NSCLC
Signal Transduction and Targeted Therapy
Study: Randomized phase III study comparing induction and concurrent aumolertinib plus definitive radiotherapy against cisplatin/pemetrexed concurrent chemoradiotherapy in unresectable EGFR-mutated stage III NSCLC. Although 98 patients were planned, only 43 were randomized before early termination; a prespecified real-world cohort of 125 patients provided additional supportive data.
Key data: Median PFS was 34.0 versus 7.4 months, HR 0.15 (95% CI 0.06–0.38). Median OS was not reached versus 30.5 months, HR 0.32, P=0.09. No grade 4–5 adverse events occurred; grade 3 radiation pneumonitis occurred in one patient receiving aumolertinib plus RT.
Why it matters: The trial raises an important question: whether selected EGFR-mutated stage III NSCLC could eventually be treated with a chemotherapy-sparing, TKI-radiotherapy approach rather than conventional chemoradiotherapy.
Clinical context & caveats: The randomized evidence is much less definitive than the “phase III” label suggests: only 43 of 98 planned patients were randomized and the trial stopped early. More importantly, the control strategy was cCRT alone rather than a contemporary LAURA-era approach incorporating consolidation EGFR inhibition. The supporting real-world analysis does not compensate for these limitations.
Targeted Therapy
Daraxonrasib shows activity across RAS-mutant NSCLC
New England Journal of Medicine
Study: Multicenter phase I/II dose-escalation and expansion study of daraxonrasib (RMC-6236), an oral multiselective RAS(ON) inhibitor, in previously treated advanced RAS-mutant NSCLC. The September publication reports 136 patients treated at doses of ≤300 mg daily.
Key data: Investigator-assessed ORR was 31% at doses ≤120 mg, 34% at 160–220 mg, and 37% at 300 mg. Grade ≥3 adverse events occurred in 54% of patients; the most common included pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%). Four grade 5 adverse events occurred.
Why it matters: Daraxonrasib represents a broader approach to RAS targeting than mutation-specific inhibitors and provides prospective evidence of antitumor activity across previously treated RAS-mutant NSCLC.
Clinical context & caveats: This remains an early-phase, uncontrolled study primarily designed to assess safety. Response rates varied across dose cohorts, and comparative efficacy, durability, optimal sequencing, and activity across individual RAS genotypes require further study.
Other Notable Publications
CNS / Imaging Biomarkers
AI-enabled early intracranial volumetric response predicts systemic PFS in the phase III CROWN study
Neuro-Oncology Advances
Study: Post-hoc analysis of 72 CROWN participants with baseline brain metastases, using the FDA-cleared VBrain platform to quantify all intracranial lesions volumetrically and compare early response with conventional target-lesion measurements.
Key data: AI-derived volumetric early tumor response was associated with systemic PFS, adjusted HR 0.44 (95% CI 0.23–0.86), whereas target-diameter early response was not, HR 0.64 (95% CI 0.29–1.41). Adding volumetric response improved discrimination over the clinical model, with ΔC-index +0.07 and AUC 0.71 versus 0.55
Why it matters: Whole-lesion volumetric assessment may capture clinically relevant early CNS response information that conventional target-lesion measurements miss.
Clinical context & caveats: This was an unplanned, post-hoc prognostic analysis, not a validation study or treatment-selection biomarker. It pooled information across treatment groups and used only 72 patients, so it should not yet influence clinical management.
SCLC
LungMate-006 — Neoadjuvant tislelizumab plus chemotherapy before surgery
MedComm
Study: Prospective single-arm phase II study of neoadjuvant tislelizumab plus platinum-etoposide in 15 patients with limited-disease SCLC, followed by curative-intent surgery where feasible.
Key data: ORR was 66.7%. Nine of 15 patients underwent surgery and all achieved R0 resection. Among surgical patients, MPR and pCR rates were 44.4% and 33.3%, respectively. Median EFS and OS in the overall cohort were 21.7 and 32.7 months.
Why it matters: Prospective perioperative data in potentially resectable SCLC remain scarce, and the study provides an early signal that neoadjuvant immunochemotherapy followed by surgery is feasible in selected patients.
Clinical context & caveats: This is an extremely small single-arm, single-center study (N=15), with only nine patients undergoing surgery and a heterogeneous stage distribution. The findings cannot establish a role for surgery or perioperative immunotherapy outside prospective investigation.
Monitoring
SYMPRO-Lung — Weekly electronic symptom monitoring associated with longer survival
The Lancet Oncology
Study: Long-term post-hoc survival analysis of the multicenter SYMPRO-Lung stepped-wedge cluster-randomized trial conducted across 14 Dutch centers. Patients with stage I–IV lung cancer starting treatment underwent either usual care or weekly online patient-reported symptom monitoring for one year. The survival analysis included 446 of 515 originally enrolled patients.
Key data: At a median follow-up of 50 months, median OS was 26 versus 21 months with symptom monitoring versus usual care. After multivariable adjustment, HR for death was 0.80 (95% CI 0.63–1.00; P=0.049). PFS was not significantly different, HR 0.86 (95% CI 0.70–1.07).
Why it matters: The findings add to evidence that structured electronic symptom monitoring may improve outcomes beyond quality of life and support incorporating PRO-based follow-up into routine lung cancer care.
Clinical context & caveats: Survival was a post-hoc outcome, not the original primary endpoint, and 13% of the initial trial population was excluded from this analysis. The adjusted OS CI reaches 1.00 and PFS was unchanged, so the survival signal should be interpreted cautiously rather than as definitive proof of causality.
Expert Takeaways
More treatment is not automatically better. SWOG/NRG S1914 provides strong randomized evidence against simply adding immunotherapy to SBRT in medically inoperable early-stage NSCLC.
ADVANCE is intriguing, but premature. The PFS HR of 0.15 deserves attention, yet 43 randomized patients and early trial termination make it insufficient to redefine treatment of EGFR-mutated stage III disease.
AI-derived imaging biomarkers are becoming more sophisticated, but remain largely prognostic. The CROWN analysis shows technical promise without demonstrating clinical utility.
Perioperative SCLC remains experimental. LungMate-006 is interesting mainly because prospective surgical data are so limited, not because 15 patients can establish a new treatment pathway.
Notes on Generalizability & Bias Signals
ADVANCE: Very small randomized population, premature closure, open-label design and a comparator that does not reflect contemporary post-cCRT EGFR-TKI treatment. The accompanying real-world cohort is supportive but nonrandomized.
SWOG/NRG S1914: Large multicenter randomized study with clinically meaningful negative results, although the population was specifically medically inoperable/high-risk early-stage disease.
CROWN AI: Retrospective post-hoc analysis of a trial subset; prognostic association does not establish predictive utility or clinical benefit from AI-guided decision-making.
LungMate-006: N=15, single-arm and highly selected; pathological-response percentages in the surgical subgroup are based on only nine patients.
Disclaimer: Publication dates refer to online-first publication.
If you found this useful, subscribe to receive next month’s synthesis.
Know a colleague who would benefit? Forward this issue.

Refer a colleague

